
Olaparib for early breast cancer with BRCA1/2 mutations
Conclusions 4 Trial OlympiA survival data demonstrate superiority over placebo in high-risk human epidermal growth factor receptor receptor 2 negative early breast cancer in women with pathogenic or possibly pathogenic germline variants of the BRCA1 or BRCA2 (gBRCA1/2pv). Why it matters This is the second prespecified interim analysis of olaparib’s benefits in high-risk early-stage breast cancer. […]